Manufacturing cell therapies is technically and financially demanding; as a result, despite therapy developers gradually strengthening their in-house expertise, they are also becoming increasingly reliant on contract service providers

Roots Analysis is pleased to announce the publication of its recent study, titled, “Cell Therapy Manufacturing Market (3rd Edition), 2019 - 2030.” 

The report features an extensive study of the current market landscape and future opportunities associated with cell therapy manufacturing. It focuses on both contract manufacturers, as well as developers with in-house manufacturing facilities, offering in-depth analyses of the various business entities that are engaged in this domain, across different global regions. Amongst other elements, the report includes:

• An analysis of the various expansion initiatives undertaken by service providers, in order to augment their respective cell therapy manufacturing capabilities, over the period 2015-2019.
• An analysis of the recent partnerships focused on the manufacturing of cell-based therapies, which have been established in the period 2014-2019.
• Informed estimates of the annual commercial and clinical demand for cell therapies, in terms of number of cells produced and area dedicated to manufacturing.
• An estimate of the overall, installed capacity for manufacturing cell-based therapies based on information reported by industry stakeholders in the public domain A competitiveness analysis of biological targets, featuring insightful pictorial summaries and representations.
• A detailed analysis of the various factors that are likely to influence the pricing of cell-based therapies, featuring different models / approaches that may be adopted by manufacturers while deciding the prices of their proprietary offerings.
• A qualitative analysis, highlighting the various factors that need to be taken into consideration by cell therapy developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
• An elaborate discussion on the role of automation technologies in improving current manufacturing methods.
• A discussion on cell therapy manufacturing regulations across various geographies, including North America, Europe, and Asia Pacific.
• Elaborate profiles of key players (industry and non-industry) that offer contract manufacturing services.
• A discussion on affiliated trends, key drivers and challenges, which are likely to impact the industry’s evolution, under a comprehensive SWOT framework.

Read Detailed Analysis: https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html     

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Type of therapy

• T-cell therapies (CAR-T therapies, TCR therapies, TIL therapies)
• Dendritic cell therapies
• Tumor cell therapies
• NK cell therapies
• Stem cell therapies

Source of cells

• Autologous
• Allogeneic

Scale of operation

• Clinical
• Commercial

Purpose of manufacturing

• Contract manufacturing
• In-house manufacturing

Key geographical regions

• North America
• Europe
• Asia Pacific
• Rest of the world

Key companies covered in the report

• BioNTech Innovative Manufacturing Services
• Cell Therapies
• Cell and Gene Therapy Catapult
• Center for Cell and Gene Therapy, Baylor College of Medicine
• Centre for Cell Manufacturing Ireland, National University of Ireland
• Clinical Cell and Vaccine Production Facility, University of Pennsylvania
• Cognate BioServices
• FUJIFILM
• Guy’s and St. Thomas’ GMP Facility, Guy’s Hospital
• Hitachi Chemical
• KBI Biopharma
• Laboratory for Cell and Gene Medicine, Stanford University
• Lonza
• MaSTherCell
• MEDINET
• Molecular and Cellular Therapeutics, University of Minnesota
• Newcastle Cellular Therapies Facility, Newcastle University
• Nikon CeLL innovation
• Rayne Cell Therapy Suite, King’s College London
• Roslin Cell Therapies
• Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre for Regenerative Medicine
• Sydney Cell and Gene Therapy
• WuXi Advanced Therapies

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html    

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

Cell therapy is one of the most promising healthcare procedure for restoration of damaged tissue. Cell therapies have huge potential for the wide range of disease treatment including tissue degradation, immune deficiency, metabolic disorders, and cancer. Cell therapy are categorized into two type’s allogeneic (cells from third party donor) and autologous (cells from one’s own body). Cell therapy has gained significant traction in recent past and currently it under commercial development. Main objective of cell therapy is to re-establish the lost function of tissues and cells rather than to produce a new organ.

Click To Continue Reading on Cell Therapy Manufacturing Market

Some cell therapies have been established and permitted for clinical trial. For instance, in 2013 a stage 2 clinical trial was completed for transplantation of bone marrow derived stem cells in affected knee by rheumatoid arthritis. The growth of this technique is also increased due to involvement of the government agencies. For instance, innovate U.K. 2014 report showed that government agreed to fund US$15.3 million in cell therapy manufacturing market.

Increasing number of surgical procedures performed across the world coupled with increasing number of trauma and accidents is propelling demand for new medical therapy. For instance, according to a 2015, World Health Organization (WHO) report, more than 50,000 stem cell transplants are carried out annually worldwide for various surgeries. Stem cells transplantation is promising medical therapy for patients with advance stage diseases like Alzheimer’s, arthritis, autism, blindness, cancer, cerebral palsy, diabetes etc. Key biopharmaceutical companies are majorly investing in research for cell therapy. For instance, Longeveron LL, a biopharmaceutical company received a US$ 750,000 grant from the Maryland Technology Development Corporation (TEDCO) in 2018 for stem cell therapy research. These collaborations and government funding are boosting growth of the cell therapy manufacturing market.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1728

Key Vendors:

Pharmicell, Merck Group, Dickinson and Company, Thermo Fisher, Lonza Group, Miltenyi Biotec GmBH, Takara Bio Group, STEMCELL Technologies, Cellular Dynamics International, Becton, Osiris Therapeutics, Bio-Rad Laboratories, Inc., Anterogen, MEDIPOST, Holostem Terapie Avanazate, Pluristem Therapeutics, Brammer Bio, CELLforCURE, Gene Therapy Catapult EUFETS, MaSTherCell, PharmaCell, Cognate BioServices and WuXi AppTec.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Visit our news Website: https://www.coherenttimes.org/